Literature DB >> 6378376

Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells.

S Karpatkin, C Ambrogio, E Pearlstein.   

Abstract

Honn et al. [Science (Wash. DC), 212: 1270, 1981] have recently reported a 93% reduction in the development of metastases of B16 amelanotic tumor cells given i.v. following a single dose of prostacyclin (PGI2) (100 micrograms) and theophylline (100 micrograms) 30 min prior to the injection of tumor cells. We have been unable to reduce pulmonary metastases induced by the i.v. injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells with a similar regimen. Thus, PGI2 and theophylline given prior to injection of tumor cells and 2 hr postinjection had no effect on the number or volume of pulmonary tumor nodules for CT26 cells, using 15 experimental and 14 control animals; Lewis lung cells, using 14 experimental and 13 control animals; or B16 amelanotic cells, using 26 experimental and 12 control animals. The PGI2 used was shown to be active in vitro, inhibiting tumor-induced platelet aggregation by all three tumors at 10(-9)M; and in vivo by inhibition of Lewis lung-induced thrombocytopenia at 1 hr, using 100 micrograms PGI2 prior to the injection of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment.

Authors:  Wei Zhang; Suying Dang; Tao Hong; Jian Tang; Jing Fan; Dawei Bu; Yanjie Sun; Zhugang Wang; Thomas Wisniewski
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

2.  Antimetastatic action of the prostacyclin analog iloprost in the mouse.

Authors:  G Sava; L Perissin; S Zorzet; P Piccini; T Giraldi
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

3.  Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis.

Authors:  Alexander Zaslavsky; Kwan-Hyuck Baek; Ryan C Lynch; Sarah Short; Jenny Grillo; Judah Folkman; Joseph E Italiano; Sandra Ryeom
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

4.  Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.

Authors:  M L Nierodzik; A Plotkin; F Kajumo; S Karpatkin
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

5.  Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors.

Authors:  F Formelli; L Cleris; R Carsana
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 6.  Prostacyclin and its analogues: antimetastatic effects and mechanisms of action.

Authors:  M R Schneider; D G Tang; M Schirner; K V Honn
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

7.  Platelet interaction with a pancreatic ascites tumor.

Authors:  J Hamilton; V Subbarao; K Granack; C Ts'ao
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

8.  Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.

Authors:  S Karpatkin; E Pearlstein; C Ambrogio; B S Coller
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

Review 9.  Fatty acid modulation of tumor cell-platelet-vessel wall interaction.

Authors:  Y Q Chen; B Liu; D G Tang; K V Honn
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

10.  Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation.

Authors:  V Costantini; P Fuschiotti; M Allegrucci; G Agnelli; G G Nenci; M C Fioretti
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.